$61.92
2.21% yesterday
Nasdaq, Mar 21, 09:02 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$61.92
-10.19 14.13% 1M
-2.20 3.43% 6M
-7.15 10.35% YTD
+4.20 7.28% 1Y
-14.66 19.14% 3Y
-1.26 1.99% 5Y
-31.48 33.70% 10Y
Nasdaq, Closing price Fri, Mar 21 2025
+1.34 2.21%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Market capitalization $11.98b
Enterprise Value $9.89b
P/E (TTM) P/E ratio 228.32
EV/FCF (TTM) EV/FCF 39.69
EV/Sales (TTM) EV/Sales 2.33
P/S ratio (TTM) P/S ratio 2.83
P/B ratio (TTM) P/B ratio 3.47
Revenue growth (TTM) Revenue growth 14.76%
Revenue (TTM) Revenue $4.24b
EBIT (operating result TTM) EBIT $80.14m
Free Cash Flow (TTM) Free Cash Flow $249.07m
Cash position $2.16b
EPS (TTM) EPS $0.27
P/E forward 14.12
P/S forward 2.57
EV/Sales forward 2.12
Short interest 5.35%
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Incyte forecast:

9x Buy
35%
16x Hold
62%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Incyte forecast:

Buy
35%
Hold
62%
Sell
4%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,241 4,241
15% 15%
100%
- Direct Costs 378 378
20% 20%
9%
3,864 3,864
14% 14%
91%
- Selling and Administrative Expenses 1,087 1,087
7% 7%
26%
- Research and Development Expense 2,607 2,607
60% 60%
61%
169 169
77% 77%
4%
- Depreciation and Amortization 89 89
8% 8%
2%
EBIT (Operating Income) EBIT 80 80
88% 88%
2%
Net Profit 33 33
95% 95%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
The Motley Fool
about 18 hours ago
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open.
Positive
Seeking Alpha
4 days ago
Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is expected to be worth $1.57 billion by 2031; Incyte can do well in biologic experienced HS patients. Regulatory discussions possible of expanded approval of OPZELURA for Prurigo Nodularis patients; Ho...
Neutral
Investopedia
5 days ago
Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,617
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today